文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌局部递送顺铂提高疗效并减少全身副作用

Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-11-27

研究分析宫颈癌患者活检和细胞系发现铂浓度低于体外有效及放疗增敏所需水平,开发顺铂负载聚合物植入物实现肿瘤局部递送,在体内联合放疗显著提高肿瘤药物特异性、降低血肾等正常器官蓄积并完全抑制肿瘤生长。

要点

  • 患者活检铂浓度仅为体外有效及放疗增敏所需水平的六分之一。
  • 局部顺铂植入物较全身给药显著提高肿瘤药物特异性并减少正常器官蓄积。
  • 局部递送联合放疗在体内完全抑制肿瘤生长。

核心结论

  • 当前顺铂全身给药提供的是亚治疗剂量,局部递送系统可向宫颈肿瘤直接递送高剂量顺铂并降低正常组织蓄积和副作用。

主要发现

  • 患者活检铂水平比体外有效及放疗增敏所需水平低6倍。
  • 局部递送植入物显著提高药物对肿瘤的特异性,并较传统全身递送显著降低血液、肾脏和其他远端正常器官的蓄积。
  • 局部治疗联合放疗在体内完全抑制肿瘤生长。

关键数值与推荐

  • 患者活检铂水平较体外有效及放疗增敏所需水平低6倍。

临床怎么用

  • 局部顺铂递送联合放疗可能作为局部和区域宫颈癌的辅助或新辅助化疗方案,有待首次人体临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cervical cancer represents the fourth most frequent malignancy in the world among women, and mortality has remained stable for the past 4 decades. Intravenous cisplatin with concurrent radiation therapy is the standard-of-care for patients with local and regional cervical cancer. However, cisplatin induces serious dose-limiting systemic toxicities and recurrence frequently occurs. In this study, we aimed to develop an intracervical drug delivery system that allows cisplatin release directly into the tumor and minimize systemic side effects. METHODS AND MATERIALS: Twenty patient biopsies and 5 cell lines treated with cisplatin were analyzed for platinum content using inductively coupled plasma mass spectrometry. Polymeric implants loaded with cisplatin were developed and evaluated for degradation and drug release. The effect of local or systemic cisplatin delivery on drug biodistribution as well as tumor burden were evaluated in vivo, in combination with radiation therapy. RESULTS: Platinum levels in patient biopsies were 6-fold lower than the levels needed for efficacy and radiosensitization in vitro. Cisplatin local delivery implant remarkably improved drug specificity to the tumor and significantly decreased accumulation in the blood, kidney, and other distant normal organs, compared with traditional systemic delivery. The localized treatment further resulted in complete inhibition of tumor growth. CONCLUSIONS: The current standard-of-care systemic administration of cisplatin provides a subtherapeutic dose. We developed a polymeric drug delivery system that delivered high doses of cisplatin directly into the cervical tumor, while lowering drug accumulation and consequent side effects in normal tissues. Moving forward, these data will be used as the basis of a future first-in-human clinical trial to test the efficacy of localized cisplatin as adjuvant or neoadjuvant chemotherapy in local and regional cervical cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Federico C, Sun J, Muz B, et al. Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile. Int J Radiat Oncol Biol Phys. 2020. PMID: 33253820. doi:10.1016/j.ijrobp.2020.11.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。